AIM VACCINE (06660): Serum-free iterative rabies vaccine has submitted pre-application for market registration.

AIM VACCINE (06660) announced that the group's independently developed serum-free iteration rabies vaccine has recently submitted a pre-application for market registration to the National Medical Products Administration. According to the results of the completed III phase clinical study, the group's serum-free iteration rabies vaccine has shown good safety, immunogenicity, and immunological durability, meeting the clinical preset goals. Compared to traditional Vero cell rabies vaccines and human diploid cell rabies vaccines, the group's serum-free iteration rabies vaccine is completely different and represents an upgraded product. Animal serum residue in vaccine products is one of the important factors that can lead to adverse reactions such as allergies in the vaccinated population. The group's serum-free iteration rabies vaccine does not contain any animal serum, significantly improving safety and reducing the probability of adverse reactions. To date, there is no serum-free rabies vaccine approved for the global market, making this product likely to become the first approved product. The group has completed the construction of a serum-free iteration rabies vaccine workshop that meets international standards and has completed commercial-scale validation production, demonstrating the capacity for large-scale production of the product. Furthermore, as the world's second-largest rabies vaccine supplier, the group is committed to leading the global rabies vaccine through deep technical iteration upgrades, providing the market with a series of rabies vaccine products of better quality and higher safety, and promoting the sustainable development of the company.